Gilead Sciences Inc. (GILD)
Summary
GILD Chart
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. (“Gilead” or the “Company”) (NASDAQ: GILD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
NEW YORK , June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") (NASDAQ: GILD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
FDA Approves Gilead's Twice-Yearly Shot for HIV Prevention
GILD wins FDA approval for Yeztugo, the first and only twice-yearly injectable PrEP for HIV prevention in the United States.
Gilead Sciences Inc. Dividends
| GILD In 2 months Estimated | Quarterly | $0.79 Per Share |
| GILD 2 weeks ago Paid | Quarterly | $0.79 Per Share |
| GILD 3 months ago Paid | Quarterly | $0.79 Per Share |
| GILD 6 months ago Paid | Quarterly | $0.77 Per Share |
| GILD 9 months ago Paid | Quarterly | $0.77 Per Share |
| GILD 14 Jun 2024 Paid | Quarterly | $0.77 Per Share |
Gilead Sciences Inc. Earnings
| 8 May 2025 Date | | 1.77 Cons. EPS | 1.81 EPS |
| 4 Feb 2025 Date | | 1.7 Cons. EPS | 1.9 EPS |
| 7 Nov 2024 Date | | 1.58 Cons. EPS | - EPS |
| 6 Nov 2024 Date | | 1.55 Cons. EPS | 2.02 EPS |
| 5 Nov 2024 Date | | 1.59 Cons. EPS | - EPS |
| GILD In 2 months Estimated | Quarterly | $0.79 Per Share |
| GILD 2 weeks ago Paid | Quarterly | $0.79 Per Share |
| GILD 3 months ago Paid | Quarterly | $0.79 Per Share |
| GILD 6 months ago Paid | Quarterly | $0.77 Per Share |
| GILD 9 months ago Paid | Quarterly | $0.77 Per Share |
| GILD 14 Jun 2024 Paid | Quarterly | $0.77 Per Share |
| 8 May 2025 Date | | 1.77 Cons. EPS | 1.81 EPS |
| 4 Feb 2025 Date | | 1.7 Cons. EPS | 1.9 EPS |
| 7 Nov 2024 Date | | 1.58 Cons. EPS | - EPS |
| 6 Nov 2024 Date | | 1.55 Cons. EPS | 2.02 EPS |
| 5 Nov 2024 Date | | 1.59 Cons. EPS | - EPS |
Gilead Sciences Inc. (GILD) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Gilead Sciences Inc. ever had a stock split?
Gilead Sciences Inc. Profile
| Drug Manufacturers - General Industry | Healthcare Sector | Mr. Daniel P. O'Day CEO | XWBO Exchange | US3755581036 ISIN |
| US Country | 17,600 Employees | 14 Mar 2025 Last Dividend | 28 Jan 2013 Last Split | 22 Jan 1992 IPO Date |
Overview
Gilead Sciences, Inc. is a frontline biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. The company's mission revolves around addressing unmet medical needs across the United States, Europe, and other international markets. Since its inception in 1987, Gilead Sciences has been committed to pushing the boundaries of scientific research to create therapeutic solutions that can significantly improve the quality of life for patients worldwide. With its headquarters in Foster City, California, Gilead stands as a pioneer in the field, forming strategic collaboration agreements with various entities including Arcus Biosciences, Inc., Merck Sharp & Dohme Corp., and many others to bolster its research and development efforts. The company's extensive portfolio underscores its dedication to combating some of today's most challenging diseases, including HIV/AIDS, COVID-19, viral hepatitis, and certain oncological disorders.
Products and Services
- HIV/AIDS treatment:
- COVID-19:
- Viral Hepatitis:
- Oncology:
- Pulmonary Arterial Hypertension:
- Severe Fungal Infections:
Gilead provides a robust lineup of products for HIV/AIDS management, including Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, Sunlencs, and Atripla. Each of these treatments plays a vital role in suppressing the virus, improving patient health, and reducing the risk of HIV transmission.
Veklury (Remdesivir) serves as an injection for intravenous use designed to treat COVID-19. It represents one of the first antiviral treatments to receive emergency use authorization for addressing the global pandemic, demonstrating efficacy in helping hospitalized patients recover faster.
Gilead offers Epclusa, Harvoni, Vemlidy, and Viread for the treatment of hepatitis B and C, contributing to the global effort to manage and potentially eliminate viral hepatitis as a major public health threat.
The company has made significant strides in cancer treatment with its products Yescarta, Tecartus, and Trodelvy, focusing on innovative therapies that can potentially transform the treatment landscape for patients suffering from various cancers.
Letairis is an oral medication developed for the treatment of pulmonary arterial hypertension (PAH), aiming to improve exercise ability and delay clinical worsening in patients.
AmBisome, a liposomal formulation, is targeted at treating serious invasive fungal infections, offering a critical solution for immunocompromised patients such as those undergoing chemotherapy or with HIV/AIDS.
Across these diverse therapeutic areas, Gilead Sciences maintains a steadfast commitment to innovation, safety, and efficacy, striving to fulfill its mission of advancing healthcare and enhancing patient outcomes around the globe.
Contact Information
